Literature DB >> 26969081

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.

Bipin N Savani1, Myriam Labopin2, Nicolaus Kröger3, Jürgen Finke4, Gerhard Ehninger5, Dietger Niederwieser6, Rainer Schwerdtfeger7, Donald Bunjes8, Bertram Glass9, Gerard Socié10, Per Ljungman11, Charles Craddock12, Frédéric Baron13, Fabio Ciceri14, Norbert Claude Gorin15, Jordi Esteve16, Christoph Schmid17, Sebastian Giebel18, Mohamad Mohty2, Arnon Nagler19.   

Abstract

The outcome of patients undergoing HLA-matched unrelated donor allogeneic hematopoietic cell transplantation following reduced-intensity conditioning or myeloablative regimens is reported to be equivalent; however, it is not known if the intensity of the conditioning impacts outcomes after mismatched unrelated donor transplantation for acute myeloid leukemia. Eight hundred and eighty three patients receiving reduced-intensity conditioning were compared with 1041 myeloablative conditioning regimen recipients in the setting of mismatched unrelated donor transplantation. The donor graft was HLA-matched at 9/10 in 872 (83.8%) and at 8/10 in 169 (16.2%) myeloablative conditioning recipients, while in the reduced-intensity conditioning cohort, 754 (85.4%) and 129 (14.6%) were matched at 9/10 and 8/10 loci, respectively. Myeloablative conditioning regimen recipients were younger, 70% being <50 years of age compared to only 30% in the reduced-intensity conditioning group (P=0.0001). Significantly, more patients had secondary acute myeloid leukemia (P=0.04) and Karnofsky Performance Status score <90% (P=0.02) in the reduced-intensity conditioning group. Patients <50 and ≥50 years were analyzed separately. On multivariate analysis and after adjusting for differences between the two groups, reduced-intensity conditioning in patients age ≥50 years was associated with higher overall survival (HR 0.78; P=0.01), leukemia-free survival (HR 0.82; P=0.05), and decreased non-relapse mortality (HR 0.73; P=0.03). Relapse incidence (HR 0.91; P=0.51) and chronic graft-versus-host disease (HR 1.31; P=0.11) were, however, not significantly different. In patients <50 years old, there were no statistically significant differences in overall survival, leukemia-free survival, relapse incidence, non-relapse mortality, and chronic graft-versus-host-disease between the groups. Our study shows no significant outcome differences in patients younger than 50 years receiving reduced-intensity vs myeloablative conditioning regimens after mismatched unrelated donor transplantation. Furthermore, the data support the superiority of reduced-intensity conditioning regimens in older adults receiving transplants from mismatched unrelated donors. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2016        PMID: 26969081      PMCID: PMC5013965          DOI: 10.3324/haematol.2015.138180

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  33 in total

1.  Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.

Authors:  A Shimoni; I Hardan; N Shem-Tov; M Yeshurun; R Yerushalmi; A Avigdor; I Ben-Bassat; A Nagler
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

2.  HLA-class II disparity is necessary for effective T cell mediated Graft-versus-Leukemia effects in NOD/scid mice engrafted with human acute lymphoblastic leukemia.

Authors:  S Stevanović; M L J van Schie; M Griffioen; J H Falkenburg
Journal:  Leukemia       Date:  2012-09-17       Impact factor: 11.528

Review 3.  Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.

Authors:  Mary Eapen; Paul O'Donnell; Claudio G Brunstein; Juan Wu; Kate Barowski; Adam Mendizabal; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-23       Impact factor: 5.742

4.  Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

Authors:  Areej El-Jawahri; Joseph Pidala; Yoshi Inamoto; Xiaoyu Chai; Nandita Khera; William A Wood; Corey Cutler; Mukta Arora; Paul A Carpenter; Jeanne Palmer; Mary Flowers; Daniel Weisdorf; Steven Pavletic; Samantha Jaglowski; Madan Jagasia; Stephanie J Lee; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

5.  Are alternative donors really still "alternative?".

Authors:  Christopher G Kanakry; Leo Luznik
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-31       Impact factor: 5.742

6.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

7.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.

Authors:  J Pidala; J Kim; M Schell; S J Lee; R Hillgruber; V Nye; E Ayala; M Alsina; B Betts; R Bookout; H F Fernandez; T Field; F L Locke; T Nishihori; J L Ochoa; L Perez; J Perkins; J Shapiro; C Tate; M Tomblyn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

Review 8.  Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist.

Authors:  Natasha Kekre; Joseph H Antin
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

9.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

Review 10.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Authors:  S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai
Journal:  Stem Cells Dev       Date:  2014-09-17       Impact factor: 3.272

View more
  9 in total

1.  Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.

Authors:  Francesca Lorentino; Myriam Labopin; Fabio Ciceri; Luca Vago; Katharina Fleischhauer; Boris Afanasyev; Nicolaus Kröger; Jan J Cornelissen; Montserrat Lovira; Ellen Meijer; Antonin Vitek; Ahmet Elmaagacli; Didier Blaise; Annalisa Ruggeri; Christian Chabannon; Arnon Nagler; Mohamad Mohty
Journal:  Leukemia       Date:  2020-05-14       Impact factor: 11.528

2.  Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.

Authors:  Eric Huselton; Michael Slade; Kathryn M Trinkaus; John F DiPersio; Peter Westervelt; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-24       Impact factor: 5.742

3.  Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Authors:  Arnon Nagler; Myriam Labopin; Bhagirathbhai Dholaria; Riitta Niittyvuopio; Johan Maertens; Xavier Poiré; Jan Cornelissen; Péter Reményi; Jean Henri Bourhis; Yves Beguin; Ram Malladi; Tessa Kerre; Wilfried Schroyens; Bipin N Savani; Mohamad Mohty
Journal:  Blood Adv       Date:  2019-07-09

4.  Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT.

Authors:  Francesco Saraceni; Myriam Labopin; Norbert-Claude Gorin; Didier Blaise; Reza Tabrizi; Liisa Volin; Jan Cornelissen; Jean-Yves Cahn; Patrice Chevallier; Charles Craddock; Depei Wu; Anne Huynh; William Arcese; Mohamad Mohty; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2016-09-02       Impact factor: 17.388

5.  Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Authors:  Nicole Santoro; Annalisa Ruggeri; Myriam Labopin; Andrea Bacigalupo; Fabio Ciceri; Zafer Gülbaş; He Huang; Boris Afanasyev; William Arcese; Depei Wu; Yener Koc; Johanna Tischer; Stella Santarone; Sebastian Giebel; Mohamad Mohty; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2017-05-30       Impact factor: 17.388

6.  Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.

Authors:  Fan Yang; Daopei Lu; Yu Hu; Xiaojun Huang; He Huang; Jing Chen; Depei Wu; Jianmin Wang; Chun Wang; Mingzhe Han; Hu Chen
Journal:  Ann Transplant       Date:  2017-06-27       Impact factor: 1.530

7.  Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Yanzhi Song; Zhichao Yin; Jie Ding; Tong Wu
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

8.  RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT.

Authors:  Frédéric Baron; Annalisa Ruggeri; Eric Beohou; Myriam Labopin; Guillermo Sanz; Noel Milpied; Mauricette Michallet; Andrea Bacigalupo; Didier Blaise; Jorge Sierra; Gérard Socié; Jan J Cornelissen; Christoph Schmid; Sebastian Giebel; Norbert-Claude Gorin; Jordi Esteve; Fabio Ciceri; Bipin N Savani; Mohamad Mohty; Eliane Gluckman; Arnon Nagler
Journal:  Oncotarget       Date:  2016-07-12

9.  Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Nelli Bejanyan; Meijie Zhang; Khalid Bo-Subait; Claudio Brunstein; Hailin Wang; Erica D Warlick; Sergio Giralt; Taiga Nishihori; Rodrigo Martino; Jakob Passweg; Ajoy Dias; Edward Copelan; Gregory Hale; Robert Peter Gale; Melhem Solh; Mohamed A Kharfan-Dabaja; Miguel Angel Diaz; Siddhartha Ganguly; Steven Gore; Leo F Verdonck; Nasheed M Hossain; Natasha Kekre; Bipin Savani; Michael Byrne; Christopher Kanakry; Mitchell S Cairo; Stefan Ciurea; Harry C Schouten; Christopher Bredeson; Reinhold Munker; Hillard Lazarus; Jean-Yves Cahn; Marjolein van Der Poel; David Rizzieri; Jean A Yared; Cesar Freytes; Jan Cerny; Mahmoud Aljurf; Neil D Palmisiano; Attaphol Pawarode; Vera Ulrike Bacher; Michael R Grunwald; Sunita Nathan; Baldeep Wirk; Gerhard C Hildebrandt; Sachiko Seo; Richard F Olsson; Biju George; Marcos de Lima; Christopher S Hourigan; Brenda M Sandmaier; Mark Litzow; Partow Kebriaei; Wael Saber; Daniel Weisdorf
Journal:  Transplant Cell Ther       Date:  2020-10-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.